After ramping up its vaccine production in South Africa, Aspen yet to receive a single order
When Aspen Pharmacare made an agreement with J&J to make and sell its own generic Covid-19 vaccine much of the world rejoiced. Aspen CEO Stephen Saad said that it would help catch Africa up to speed with the rest of the world, and President Joe Biden’s administration agreed and pledged $200 million to the plant in Gqeberha to expand production.
But now, despite being the first factory in Africa to make vaccines for the continent, the pharma has not received a single order, which could lead to the shuttering of the site, according to a recent report from The New York Times.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.